KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Accured Expenses (2017 - 2025)

Bionano Genomics' Change in Accured Expenses history spans 7 years, with the latest figure at $721000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 85.82% year-over-year to $721000.0; the TTM value through Sep 2025 reached -$1.4 million, up 72.89%, while the annual FY2024 figure was -$2.0 million, 21.02% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $721000.0 at Bionano Genomics, up from -$1.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.5 million in Q3 2022 and bottomed at -$5.3 million in Q2 2024.
  • The 5-year median for Change in Accured Expenses is -$443000.0 (2022), against an average of -$67947.4.
  • The largest annual shift saw Change in Accured Expenses surged 680.11% in 2021 before it crashed 1073.1% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$145000.0 in 2021, then plummeted by 1073.1% to -$1.7 million in 2022, then tumbled by 105.11% to -$3.5 million in 2023, then surged by 91.34% to -$302000.0 in 2024, then surged by 338.74% to $721000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Change in Accured Expenses are $721000.0 (Q3 2025), -$1.3 million (Q2 2025), and -$488000.0 (Q1 2025).